HOME >> BIOLOGY >> NEWS
Towards targeted lung cancer treatment

Better understanding of the mechanisms underlying cancer development has lead to the development of new anti-cancer drugs aimed at specific molecular targets. Because cancer is a heterogeneous disease, however, many of these new drugs work only in a subset of patients. They are also expensive, and they can have serious side effects. Scientists are therefore trying to find ways to predict who will benefit from a particular drug, so that they can better weigh the risks and benefits for an individual patient. In an article in the current issue of the international open-access medical journal PLoS Medicine, William Pao, Harold Varmus, and colleagues from Memorial Sloan Kettering Cancer Center in New York report results that might lead to more "targeted therapy" for lung cancer patients.

The researchers had previously shown that the epidermal growth factor (EGF) receptor, a tyrosine kinase, is often mutated in non-small-cell lung cancers, and that tumors that harbor such mutations are sensitive to two drugs called gefitinib and erlotinib. In the new study, they focused on a signaling protein called KRAS. The KRAS gene is also often mutated in lung cancers, but very few cancers have mutations in both the EGF receptor and the KRAS gene. The researchers found that those patients whose tumors had KRAS mutations had not shown an anti-tumor response when they were treated with either erlotinib or gefitinib.

These findings need to be validated by additional studies. If they are confirmed, it means that doctors should analyze tumors for mutations in the EGF receptor and KRAS before they decide whom to treat with erlotinib or gefitinib.


'"/>

Contact: Paul Ocampo
pocampo@plos.org
1-415-624-1224
Public Library of Science
24-Jan-2005


Page: 1

Related biology news :

1. Dengue and other hemorrhagic fevers: Towards a first potential treatment
2. Towards predicting late-stage radiation toxicity
3. Towards the mechanism of cell respiration
4. Towards a unified model of transcription termination
5. Towards a cheap and easy way to monitor HIV/AIDS
6. Genomic signatures identify targeted therapies for lung cancer
7. Nanocomposite labeled cancer cells can be targeted and destroyed using lasers
8. Progress toward a targeted therapy for a specific form of leukemia
9. NDDO and ESMO joined by US National Cancer Institute in conferences on targeted cancer therapies
10. Biomarkers of response to VEGF pathway-targeted therapy discovered for renal cell carcinoma
11. Light activated anticancer drug targeted to DNA using cisplatin like sub-units

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selector™ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid biopsies ... the optimal patient population and timing of blood sampling may improve the value ...
(Date:12/7/2016)... Neogen Corporation (NASDAQ: NEOG ) ... as its chief science officer — a new ... at Neogen effective Jan. 1. Kephart has ... unit of Thermo Fisher Scientific, as well as animal ... extensive industry experience also includes the management of a ...
Breaking Biology Technology:
Cached News: